Flanvotumab

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]

Flanvotumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9986N1714O2018S46
Molar mass145545.80 g·mol−1
 NY (what is this?)  (verify)

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.